Asset Program

Ready-to-use, AI-Validated Drug Candidate Packages

The Asset Program represents a portfolio of pre-validated drug candidates verified through in silico screening and binding affinity assays. It mitigates early discovery-stage risks while ensuring a seamless pipeline from research and development through to commercialization.

Why Syntekabio Asset Program

Ready-to-Go Package

Ready-to-use drug candidate packages validated through proactive discovery and in silico verification

Eliminates early-stage exploration uncertainties and enables rapid R&D initiation.

From Research to Business

Seamless execution framework from research to commercialization

Supports the entire pipeline from PoC validation through collaborative research, follow-on development, and licensing-out.

Platform-Validated Quality

Consistent reproducibility and reliability verified through AI platform.

Derived from Syntekabio's proprietary AI platform and integrated analysis pipeline, it offers reliable criteria for subsequent research and development.

Asset Program List

No	Target Protein	Indications	Mechanism of Action	Marketed drugs / Pipeline Drugs
1	BCL2	Hematologic malignancies (CLL, AML, etc.)	Inhibition of apoptosis-regulating protein	Venetoclax
2	BTK	B-cell lymphoma, Autoimmune diseases	Inhibition of B-cell receptor signaling	Ibrutinib, Acalabrutinib, Zanubrutinib
3	CDK2/4/6	Breast cancer, Solid tumors	Inhibition of cell cycle progression	Palbociclib, Ribociclib, Abemaciclib
4	FGFR1/2/3	Cholangiocarcinoma, Bladder cancer, etc.	Inhibition of FGFR signaling	Erdafitinib, Pemigatinib, Futibatinib
5	KRAS	Non-small cell lung cancer, Colorectal cancer	Inhibition of KRAS G12C mutation	Sotorasib, Adagrasib
6	MCLI	Hematologic malignancies	Inhibition of anti-apoptotic protein	S64315, AMG 176
7	MDM2	Solid tumors, Hematologic malignancies	Inhibition of p53 degradation → Activation of tumor suppression	Idasanutlin, BI-907828
8	PIK3CA	Breast cancer, Lymphoma	Inhibition of PI3K-AKT pathway	Alpelisib, Copanlisib
9	TYK2	Psoriasis, Lupus	Selective inhibition of TYK2 in JAK-STAT pathway	Deucravacitinib
10	EGFR	Non-small cell lung cancer, Colorectal cancer	Inhibition of EGFR signaling	Osimertinib, Erotinib, Gefitinib
11	JAK1/2/3/TEC	Autoimmune diseases, Myelofibrosis	Inhibition of JAK/STAT pathway	Rusolitinib, Tofacitinib, Baricitinib
12	NLRP3	Inflammatory diseases	Inhibition of inflammasome	DFV890, Inzomelid
13	ROCK1/2	Fibrosis, Glaucoma	Inhibition of cytoskeleton regulatory pathway	Netarsudil, Ripasudil
14	S1PR1	Multiple sclerosis	Inhibition of lymphocyte migration	Fingolimod, Ozanimod
15	GLP1R	Type 2 diabetes, Obesity	GLP-1 receptor agonism → Promotion of insulin secretion	Semaglutide, Tirzepatide
16	MAPT	Alzheimer's disease, Parkinson's disease	Inhibition of Tau protein aggregation	TAU360, LMTM
17	PDE10A	Schizophrenia, Parkinson's disease	Regulation of dopamine signaling	Papaverine derivatives
18	KCNQ2/3	Epilepsy	Regulation of neuronal excitability	Ezogabine
19	PDE4/4A/4B/4D/4C	Inflammatory and psychiatric disorders	Inhibition of cAMP degradation → Anti-inflammatory effect	Roflumilast, Apremilast
20	PCSK9	Dyslipidemia	Inhibition of LDL receptor degradation	MK-0616 (oral PCSK9i)

Asset Program Use Cases

Rapid Proof-Of-Concept (PoC) Validation

Deploy pre-validated candidates immediately to minimize development risks with minimal investment.

Enhanced Competitiveness in Collaborative Research And Proposals

Leverage AI-analyzed and validated candidates to strengthen competitiveness and enhance partnership success rates.

Rapid Expansion of New Targets And Pipelines

Accelerate portfolio expansion by incorporating pre-screened novel candidate packages from large-scale in silico screening into early-stage pipelines.

Syntekabio AI Platform Ensuring Asset Credibility

SM-ARS®

Rapidly derives high-quality, synthetically accessible candidates from a library of over 10 billion compounds using AI platforms.

AB-ARS®

Select optimal candidates by predicting antibody binding affinity and developability through AI-based automated CDR design.

DEEPMATCHER®

Predicts target-compound complex structures to select compounds with high molecular-model reliability.

LM-VS™

Predicts promising novel candidates with high development potential through AI screening based on target protein 3D structures.

FAQ

Looking for specific targets? Explore our portfolio of AI-based drug candidates and access detailed data now.

Contact UsContact Us